Mast Therapeutics (MSTX) Reports In-Line Q3 EPS
Tweet
Share
E-mailGet Alerts MSTX Hot Sheet
Join SI Premium – FREE
Mast Therapeutics (NYSE: MSTX) reported Q3 EPS of ($0.06), in-line with the analyst estimate of ($0.06).
For earnings history and earnings-related data on Mast Therapeutics (MSTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
- Acrivon Therapeutics, Inc. (ACRV) Tops Q2 EPS by 21c
- FGI Industries Ltd (FGI) Tops Q2 EPS by 59c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
